AG真人官方

PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- (Nasdaq: VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global聽Transportation and Security, and Global Workplaces and AG真人官方 Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.

Enrietti's over 20-year career includes 10 years of experience with Viatris and its legacy companies, most recently serving as Chief People Officer. Throughout his tenure at Viatris, he has also played a key role in numerous successful business transactions and integrations. With expertise spanning financial services, M&A, talent strategy, organizational effectiveness, employee experience and total rewards, he has been instrumental in supporting the Board of Directors and senior management team in achieving business objectives and driving transformation.

"I am excited to have Andrew take on this important new role as Chief Administrative and Transformation Officer," said , CEO of Viatris. "His deep understanding of our organization, combined with his proven ability to deliver results and his people-first leadership style, will be instrumental as we continue to finalize and then execute our enterprise-wide strategic review and position Viatris for long-term, sustainable growth."

"I'm honored to take on this new role at such a pivotal moment for Viatris," said , Chief Administrative and Transformation Officer. "The structure we are creating represents a great opportunity to help shape the future of our organization by bringing together critical functions that will drive our transformation and long-term growth. I look forward to continuing to work closely with Scott, our Board of Directors, the Executive Leadership Team, and colleagues across the company to build on our momentum and position Viatris for continued success."

About Viatris
(Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and

Hyderabad, India. Learn more at and , and connect with us on , , and (formerly Twitter).

Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that his聽deep understanding of our organization, combined with his proven ability to deliver results and his people-first leadership style, will be instrumental as we continue to finalize and then execute our enterprise-wide strategic review and position Viatris for long-term, sustainable growth; the structure we are creating represents a great opportunity to help shape the future of our organization by bringing together critical functions that will drive our transformation and long-term growth; and I look forward to continuing to work closely with Scott, our Board of Directors, the Executive Leadership Team, and colleagues across the company to build on our momentum and position Viatris for continued success. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.

View original content to download multimedia:

SOURCE Viatris Inc.